CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Agios Pharmaceuticals, Inc. (AGIO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Agios Pharmaceuticals, Inc. (AGIO)

Pharmaceutical Preparations · market cap $2.1B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-03-15 (est.)
Phase 2
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Agios Pharmaceuticals (AGIO) is a Cambridge, MA-based company focused on genetically defined diseases, with a near-term emphasis on hemolytic anemias. Our data shows a $2.2B market cap, 536 employees and mitapivat as the lead asset (Phase 3 in sickle cell disease). A mitapivat PDUFA date is on our calendar for 2026-11-01, five days after this note's date, followed by earnings on 2026-11-05.
The catalyst path
  • 2027-03-15 (est.)Phase 2 · AG-120imp 7/10
Pipeline
AssetPhaseIndication
TebapivatPhase 2Myelodysplastic Syndromes
MitapivatPhase 3Sickle Cell Disease
AG-348Phase 3Pyruvate Kinase Deficiency
EnasidenibPhase 2Hematologic Neoplasms
AG-120Phase 2Chondrosarcoma
ivosidenib and nivolumabPhase 2Advanced Solid Tumor
Price & technical context
3-month
-6.1%
6-month
+12.1%
12-month
-27.6%
52-wk range
$22.34–$45.49
vs 50-day MA
-4.5%
vs 200-day MA
-0.8%
Realized vol
94.3%
Max drawdown
-63.8%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for AGIO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.